SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion Therapeutics filed an 8-K reporting the results of its 2026…

Esperion Therapeutics, Inc. · 8-K filed Jun 1, 2026 at 16:22 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 1, 2026 at 16:22 ET

Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026. Stockholders approved all four proposals, including the re-election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), a non-binding advisory vote on executive compensation, ratification of Ernst & Young as independent auditor, and a Fourth Amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 to a total of 30,150,000 shares. This is a routine post-meeting filing with no material financial impact.

  • Annual meeting held May 28, 2026; all four stockholder proposals approved.
  • Class I directors J. Martin Carroll and Sheldon L. Koenig re-elected.
  • Fourth Amendment to 2022 Stock Option and Incentive Plan approved, increasing authorized shares by 7,000,000 to 30,150,000 total.
  • 257,404,876 shares of common stock outstanding as of March 31, 2026 record date.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access